GLI1 and breast cancer: The basal expression levels of GLI1 and GLI2 downstream of the Hh ligand in TNBC are higher than those in hormone receptor-positive (HR+) breast cancer, and the prognosis of breast cancer patients with high GLI1 expression is poor[20].